Results 61 to 70 of about 1,325,573 (304)

Going viral − Virus‐targeting nanobodies for research, diagnostics and therapy

FEBS Letters, EarlyView.
The increasing prevalence of viral diseases represents a major threat for global human health. Nanobodies, small binding fragments derived from camelid heavy‐chain antibodies, offer versatile tools for viral research, diagnostics, and antiviral therapy.
Domenic Ebert, Ulrich Rothbauer
wiley   +1 more source

MONOCLONAL ANTIBODIES

Hematology, Transfusion and Cell Therapy
Obinutuzumab, an anti CD-20 monoclonal antibody, can be used in combination with venetoclax, ibrutinib or acalabrutinib in CLL patients with newly diagnosed or relaps patient's treatment indications. Another anti CD-20 monoclonal antibody, rituximab, has
Zekeriya Aksöz
doaj   +1 more source

Unlocking the potential of cell‐permeable nanobodies for intracellular applications

FEBS Letters, EarlyView.
This review outlines current strategies for delivery of nanobodies into cells and highlights recent examples of functional applications. By addressing and manipulating intracellular targets, these molecules hold great potential for treating cancer, respiratory diseases and neurological disorders, making this a vibrant area of research in the biomedical
Mariona Gené‐Verdés, Luise Franz, Christian P.R. Hackenberger   +2 more
wiley   +1 more source

Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells [PDF]

, 2008
Background: The hemagglutinin (HA) glycoprotein is the principal target of protective humoral immune responses to influenza virus infections but such antibody responses only provide efficient protection against a narrow spectrum of HA antigenic variants ...
Poon Leo L. M., Carsetti Rita, Cinatl, J, Cox Freek, Guan, Yi, Ignace Lasters, Brink, Edward van den, Jongeneelen, M, ter Meulen Jan, Edward van den Brink, de Kruif John, Cinatl Jindrich, van Deventer, E, Peiris, M, Jaap Goudsmit, Carsetti, Rita, Throsby, Mark, Carsetti, R., Leo L M Poon, Cornelissen, L., Arjen Bakker, Kruijf, C.G., de, Throsby Mark, Lasters, I., Rita Carsetti, de Kruif, J, Poon, L.L.M., Freek Cox, Yi Guan, Goudsmit, J., Lisette Cornelissen, Els van Deventer, Cornelissen Lisette, Jongeneelen Mandy, Alard Philippe, Goudsmit Jaap, Guan Yi, Guan, Y, Alard, P., Brink, E., van den, Peiris Malik, Deventer, Els van, Kruif, John de, Cinatl, J., John de Kruif, Jan ter Meulen, Cornelissen, L, Cox, F, Cox, Freek, Goudsmit, J, Cox, F., Poon, LLM, Bakker, A.B.H., Jindrich Cinatl, Lasters, Ignace, Jongeneelen, M., van Deventer Els, Mandy Jongeneelen, Poon, Leo L. M., Meulen, J., van der, Bakker, Arjen, Cinatl, Jindrich, van den Brink, E, Malik Peiris, Peiris, Malik, van den Brink Edward, Deventer, W.B.E., van, Bakker, A, Bakker Arjen, Mark Throsby, Throsby, M., Lasters, I, Guan, Y., Alard, Philippe, ter Meulen, J, Carsetti, R, Philippe Alard, Cornelissen, Lisette, Goudsmit, Jaap, Jongeneelen, Mandy, Peiris, M., Throsby, M, Meulen, Jan ter, Alard, P, Lasters Ignace   +84 more
core   +1 more source

KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer

Molecular Oncology, EarlyView.
Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan, Veronika M Metzler, Simone de Brot, Corinne L Woodcock, Anna E Harris, Jennifer Lothion‐Roy, Emeli M Nilsson, Atara Ntekim, Michael S Toss, Jenny L Persson, Francesca Khani, Brian D Robinson, Lorraine J Gudas, Emad Rakha, David M Heery, Catrin S Rutland, Nigel P Mongan   +16 more
wiley   +1 more source

Generation and characterization of rat and mouse monoclonal antibodies specific for MeCP2 and their use in X-inactivation studies [PDF]

, 2011
Methyl CpG binding protein 2 (MeCP2) binds DNA, and has a preference for methylated CpGs and, hence, in cells, it accumulates in heterochromatin. Even though it is expressed ubiquitously MeCP2 is particularly important during neuronal maturation. This is
Rottach Andrea, Jost, K.L., Becker, Annette, Andrea Rottach, Leonhardt, Heinrich, Becker, A., Manel Esteller, Esteller, Manel, K Laurence Jost, Wolf, P., Jost K. Laurence, Wolf, Patricia, Cardoso, M. Cristina, Leonhardt Heinrich, Paolo Petazzi, Huertas Dori, Annette Becker, Cardoso M. Cristina, Patricia Wolf, Milden Manuela, Wolf Patricia, Esteller Manel, K. Laurence Jost, Bertulat Bianca, Dori Huertas, Milden, M., Huertas, D., Juan Sandoval, Bianca Bertulat, Sandoval, Juan, M. Cristina Cardoso, Bertulat, B., Kremmer Elisabeth, Petazzi Paolo, Milden, Manuela, Huertas, Dori, Becker Annette, Rottach, A., Jost, K. Laurence, Sandoval, J., Esteller, M., Kremmer, E., Manuela Milden, Kremmer, Elisabeth, Cardoso, M.C., Heinrich Leonhardt, Sandoval Juan, Petazzi, Paolo, Petazzi, P., M Cristina Cardoso, Bertulat, Bianca, Rottach, Andrea, Elisabeth Kremmer, Leonhardt, H., Esteller, Manel, 1968-   +54 more
core   +2 more sources

MONOCLONAL ANTIBODY FOR MULTIPLE SCLEROSIS TREATMENT

Медицинский совет, 2017
Monoclonal antibodies are widely used in various fields of modern medicine, for example, in oncology, rheumatology, gastroenterology, transplantation.
E. V. Popova
doaj   +1 more source

Signaling dependent and independent mechanisms in pemphigus vulgaris blister formation. [PDF]

PLoS ONE, 2012
Pemphigus vulgaris (PV) is an autoimmune epidermal blistering disease caused by autoantibodies directed against the desmosomal cadherin desmoglein-3 (Dsg3). Significant advances in our understanding of pemphigus pathomechanisms have been derived from the
Masataka Saito, Sara N Stahley, Christopher Y Caughman, Xuming Mao, Dana K Tucker, Aimee S Payne, Masayuki Amagai, Andrew P Kowalczyk   +7 more
doaj   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source

Special Issue: Monoclonal Antibodies

Antibodies, 2018
Monoclonal antibodies are utilized in clinical practice for the treatment of various diseases including cancer, autoimmunity, metabolic and infectious diseases [...]
Christian Klein
doaj   +1 more source